METHOD OF PREDICTING “SUPER RESPONSE” TO CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH COMPLETE LEFT BUNDLE BRANCH BLOCK AND CHRONIC HEART FAILURE OF VARIOUS ETIOLOGIES Russian patent published in 2024 - IPC A61B5/02 G01T1/164 

FIELD: medicine; cardiology.

SUBSTANCE: invention can be used to predict the “super response” to cardiac resynchronization therapy in patients with chronic heart failure of various etiologies. Myocardial perfusion scintigraphy is performed with ^99mTc-methoxy-isobutyl-isonitrile, synchronized with electrocardiography. The sum of ^99mTc-methoxy-isobutyl-isonitrile perfusion impairment scores at rest (SRS) is determined. Radionuclide equilibrium tomoventriculography is performed. The value of the phase standard deviation of the anterior wall of the left ventricle (LVAW SD) is determined, after which the prognostic probability of a “super response” to cardiac resynchronization therapy is determined using the formula

where P is the predictive probability, e is the base of the natural logarithm (e = 2.7182818284), x1 is SRS, x2 is LVAW SD. A P value greater than 0.292 predicts a “super response” to cardiac resynchronization therapy.

EFFECT: method makes it possible to increase the effectiveness of cardiac resynchronization therapy and optimize the selection of patient candidates for implantation of a cardiac resynchronization device by predicting a “super response” to cardiac resynchronization therapy.

1 cl, 1 dwg, 3 tbl, 4 ex